View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 24, 2021updated 25 Feb 2021 9:40am

Regeneron’s antibodies demonstrate promise against MERS-CoV in NIH trial

The US National Institutes of Health (NIH) has reported that the Phase I clinical trial of Regeneron’s two monoclonal antibodies (mAbs) directed against the Middle East respiratory syndrome coronavirus (MERS-CoV) was shown to be well tolerated and safe when administered simultaneously to healthy adults.

The US National Institutes of Health (NIH) has reported that the Phase I clinical trial of Regeneron’s two monoclonal antibodies (mAbs) directed against the Middle East respiratory syndrome coronavirus (MERS-CoV) was shown to be well tolerated and safe when administered simultaneously to healthy adults.

The investigational mAbs, REGN3048 and REGN3051 are discovered and developed by Regeneron and target the MERS-CoV spike protein used by the virus to bind to and infect cells.

In 2012, the first recognised case of MERS was reported in Jordan.

Sponsored by the NIH unit National Institute of Allergy and Infectious Diseases (NIAID), the randomised, placebo-controlled trial is the first to analyse experimental antibodies in humans.

It was carried out at a clinical trial site in California, WCCT Global, enrolling 48 healthy adult participants, with 36 receiving mAbs.

They were given an intravenous infusion of mAbs or placebo and followed up for 121 days.

The NIH noted that no serious adverse events were observed in the antibody trial.

Researchers at Regeneron and the University of Maryland, College Park gave REGN3048 and REGN3051 sequentially and in combination to genetically modified mice that can be infected with MERS-CoV, in preclinical studies.

Data showed that both the mAbs, on administration one day before coronavirus exposure, lowered virus levels later detected in the lungs, while co-administration was more effective in providing protective effects than either of the mAb alone.

Furthermore, co-administering the mAbs a day after MERS-CoV exposure reduced viral levels and lowered tissue damage in the lungs of the mice versus mice receiving placebo.

The latest findings and the preclinical data indicate the potential efficacy and use of monoclonal antibody therapy for preventing or treating MERS-CoV. It also sets the basis for developing spike-targeted mAb therapies for other infectious diseases such as SARS-CoV-2.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU